Harpoon Therapeutics Inc (HARP)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Luke B. Evnin
Employees:
45
4000 SHORELINE CT #250, SOUTH SAN FRANCISCO, CA 94080
650-443-7400

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Data derived from most recent annual or quarterly report
Market Cap 169.31 Million Shares Outstanding32.749 Million Avg 30-day Volume 216.309 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.47
Price to Revenue29.3858 Debt to Equity0.0 EBITDA-96.906 Million
Price to Book Value6.6458 Operating Margin-431.731 Enterprise Value440.996 Million
Current Ratio2.387 EPS Growth0 Quick Ratio2.337
1 Yr BETA 0.8501 52-week High/Low 24.2 / 5.15 Profit Margin-427.9174
Operating Cash Flow Growth0.0 Altman Z-Score0.7878 Free Cash Flow to Firm 67.048 Million
View SEC Filings from HARP instead.

View recent insider trading info

Funds Holding HARP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HARP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ERBEZ GEORGIA CHIEF FINANCIAL OFFICER

  • Officer
115,000 2021-11-11 4

SACKS NATALIE CHIEF MEDICAL OFFICER

  • Officer
155,000 2021-11-11 2

WESCHE HOLGER CHIEF SCIENTIFIC OFFICER

  • Officer
135,000 2021-11-11 4

EASTLAND JULIA MARIE PRESIDENT AND CEO

  • Officer
  • Director
350,000 2021-11-08 3

MYERS SCOTT DUNSETH

  • Director
10,167 2021-10-25 3

GADICKE ANSBERT

ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

MPM ONCOLOGY IMPACT MANAGEMENT LP

MPM ONCOLOGY IMPACT MANAGEMENT GP LLC

UBS ONCOLOGY IMPACT FUND L.P.

  • 10% Owner
6,328,095 2021-05-28 13

BAILES JOSEPH S

  • Director
10,167 2021-05-04 2

HUNT RONALD

  • Director
  • 10% Owner
14,974 2021-05-04 2

COLOWICK ALAN

  • Director
10,167 2021-05-04 4

DRACHMAN JONATHAN G

  • Director
10,167 2021-05-04 2

ROBBINS ANDREW R

  • Director
10,167 2021-05-04 2

CHIN MARK

  • Director
13,184 2021-05-04 2

VINEY JOANNE L.

  • Director
12,820 2021-05-04 2

MPM BIOVENTURES 2014, L.P.

MPM ASSET MANAGEMENT LLC

MPM BIOVENTURES 2014 (B), L.P.

MPM ASSET MANAGEMENT INVESTORS BV2014 LLC

MPM BIOVENTURES 2014 LLC

MPM BIOVENTURES 2014 GP LLC

FOLEY TODD

EVNIN LUKE

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2021-04-15 2

MPM BIOVENTURES 2014, L.P.

MPM ASSET MANAGEMENT LLC

MPM BIOVENTURES 2014 (B), L.P.

MPM ASSET MANAGEMENT INVESTORS BV2014 LLC

MPM BIOVENTURES 2014 LLC

MPM BIOVENTURES 2014 GP LLC

FOLEY TODD

GADICKE ANSBERT

EVNIN LUKE

  • 10% Owner
7,136,728 2021-02-10 4

MCMAHON GERALD PHD PRESIDENT AND CEO

  • Officer
  • Director
0 2021-01-28 1

NEW LEAF VENTURES III, L.P.

NEW LEAF VENTURE ASSOCIATES III, L.P.

NEW LEAF VENTURE MANAGEMENT III, L.L.C.

NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

NEW LEAF BPO ASSOCIATES II, L.P.

NEW LEAF BPO MANAGEMENT II, L.L.C

  • 10% Owner
3,156,699 2021-01-11 0

EVNIN LUKE

  • Director
  • 10% Owner
0 2020-05-28 2

BAEUERLE PATRICK

  • Director
0 2020-05-28 0

ARIX BIOSCIENCE PLC

ARIX BIOSCIENCE HOLDINGS LTD

  • 10% Owner
2,193,704 2020-05-27 0

GADICKE ANSBERT

  • 10% Owner
41,538,405 2019-02-12 13

MPM BIOVENTURES 2014, L.P.

MPM ASSET MANAGEMENT LLC

MPM BIOVENTURES 2014 (B), L.P.

MPM ASSET MANAGEMENT INVESTORS BV2014 LLC

MPM BIOVENTURES 2014 LLC

MPM BIOVENTURES 2014 GP LLC

FOLEY TODD

  • 10% Owner
22,191,834 2019-02-12 4

UBS ONCOLOGY IMPACT FUND L.P.

ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

MPM ONCOLOGY IMPACT MANAGEMENT LP

MPM ONCOLOGY IMPACT MANAGEMENT GP LLC

  • 10% Owner
3,898,422 2019-02-12 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
HARPOON THERAPEUTICS INC HARP 2022-01-21 22:15:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 21:45:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 21:15:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 20:45:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 20:15:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 19:45:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 19:15:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 18:45:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 18:15:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 17:45:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 17:15:03 UTC -0.3638 0.4338 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 16:45:03 UTC -0.3674 0.4374 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 16:15:03 UTC -0.3674 0.4374 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 15:45:03 UTC -0.3626 0.4326 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 15:15:03 UTC -0.3626 0.4326 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 14:45:03 UTC -0.3626 0.4326 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 14:15:03 UTC -0.3626 0.4326 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 13:45:03 UTC -0.363 0.433 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 13:15:03 UTC -0.363 0.433 200000
HARPOON THERAPEUTICS INC HARP 2022-01-21 12:45:03 UTC -0.363 0.433 200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund HARP -4.0 shares, $-46.32 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund HARP -1.0 shares, $-11.58 2020-03-31 N-PORT

Elevate your investments